{"id":2063,"date":"2017-10-01T01:00:00","date_gmt":"2017-10-01T00:00:00","guid":{"rendered":"https:\/\/angh.net\/abstracts\/description-de-la-population-incluse-dans-letude-de-surveillance-des-porteurs-inactifs-de-lantigene-hbs-pibac-2\/"},"modified":"2018-10-20T18:40:22","modified_gmt":"2018-10-20T16:40:22","slug":"description-de-la-population-incluse-dans-letude-de-surveillance-des-porteurs-inactifs-de-lantigene-hbs-pibac-2","status":"publish","type":"post","link":"https:\/\/angh.net\/abstracts\/description-de-la-population-incluse-dans-letude-de-surveillance-des-porteurs-inactifs-de-lantigene-hbs-pibac-2\/","title":{"rendered":"Description de la population incluse dans l\u2019\u00e9tude de surveillance des porteurs inactifs de l\u2019antig\u00e8ne HBs (PIBAC)."},"content":{"rendered":"<p><strong>2017<\/strong><\/p>\n<p><em>Marone D (1), Causse X (1), Potier P (1), Labadie H (1), Macaigne G (1), Cadranel JF (1), Salloum H (1), Henrion J (1), Renou C (1), Zanditenas D (1), Hommel S (1), Ollivier-Hourmand I (3), Arpurt JP (1), Bresson-Hadni S (2), Fontanges T (2), Schnee M (1), Boyer N (2), Bettan L (1), Cosconea-Cioaca S (1), Heluwaert F (1), Castelnau C (2), Rosa I (1), Beorchia S (2), Hanslik B (2), Bonny C (2), Roque-Afonso AM (4), pour l\u2019ANGH (1), le CREGG (2), le CHU de Caen (3), le CHU Paul Brousse (4).<\/em><\/p>\n<p><strong>H\u00e9patologie <\/strong>&#8211; \u00a02017-04-21 &#8211;\u00a0CO &#8211;<\/p>\n<p>________________________________<\/p>\n<p>En 2012, les recommandations de l\u2019EASL ont consid\u00e9r\u00e9 comme porteurs inactifs du VHB les patients porteurs d\u2019AgHBs, d\u2019anticorps anti-HBc et anti-HBe, sans surinfection virale, sans signe d\u2019h\u00e9patopathie \u00e9volu\u00e9e, dont les transaminases ALT \u00e9taient constamment normales et la charge virale &lt; 20000 UI\/ml (surveillance tous les 3 ou 4 mois pendant au minimum 1 an), alors que le seuil de charge virale retenu dans les pr\u00e9c\u00e9dentes recommandations (2009) \u00e9tait de 2000 UI\/ml. La quantification de l\u2019AgHBs semble aussi pouvoir aider \u00e0 identifier les porteurs inactifs du VHB (&lt; 1000 UI\/ml pour le g\u00e9notype D, &lt; 100 UI\/ml pour les g\u00e9notypes B et C). Plus r\u00e9cemment, un Ag HBcr (core-related)  20000 UI\/ml, n = 3 ; charge virale ind\u00e9tectable et AgHBs non quantifiable, n = 10 ; pas de charge virale renseign\u00e9e \u00e0 l\u2019inclusion, n = 43. La population \u00e9tudi\u00e9e est donc de 496 patients, 455 en consultation hospitali\u00e8re (91,7%), 41 en consultation lib\u00e9rale (8,3%).<br \/>\nOn compte 52% de femmes, 48% d\u2019hommes (sex ratio 0,91), d\u2019un \u00e2ge moyen de 42 ans + 12 (extr\u00eames 19-79).<br \/>\nLes inclus \u00e9taient originaires d\u2019Afrique sub-saharienne (46 %), d\u2019Asie du sud-est (13%), de France m\u00e9tropolitaine (13%), du Maghreb (11%), d\u2019Europe occidentale ou d\u2019Am\u00e9rique du nord (8 %), d\u2019Europe de l\u2019est (3%), des territoires fran\u00e7ais d\u2019outre-mer (3%), du Moyen Orient (2%) ou d\u2019ailleurs (1%), ce qui est tr\u00e8s proche des donn\u00e9es de l\u2019INVS sur les patients infect\u00e9s par le VHB et vivant en France m\u00e9tropolitaine.<br \/>\nCes patients d\u00e9claraient une consommation quotidienne moyenne d\u2019alcool : nulle (89%),  30 g (2%) ; de tabac : nulle (90%),  20 g (1%) ; de cannabis : nulle (99%), occasionnelle (0,4%), quotidienne (0,6%).<br \/>\n2,9% des inclus avaient un IMC &lt; 18,5 (maigreur), 43,1% un poids normal (IMC entre 18,5 et 24,9), 36,8% un surpoids (IMC entre 25 et 29,9), 12,8% une ob\u00e9sit\u00e9 de classe 1 (IMC entre 30 et 34,9), 3,6% une ob\u00e9sit\u00e9 de classe 2 (IMC entre 35 et 39,9), 0,8% une ob\u00e9sit\u00e9 de classe 3 (IMC de 40 et +), ce qui est comparable aux donn\u00e9es d\u2019OBEPI 2012.<br \/>\nLa charge virale B \u00e0 l\u2019inclusion chez les 496 patients analysables \u00e9tait: ind\u00e9tectable chez 10,3% ; quantifiable et  2000 et &lt; 20000 UI\/ml chez 18,1%.<br \/>\nLa quantification de l\u2019AgHBs \u00e9tait &lt; 100 UI\/ml pour 17,3% de ces patients, entre 100 et 999 UI\/ml pour 23,9% d\u2019entre eux et de 1000 UI\/ml ou+ chez 58,9%.<br \/>\nLe g\u00e9notype a pu \u00eatre cherch\u00e9 chez 425 patients, il n\u2019\u00e9tait pas r\u00e9alisable chez 112 d\u2019entre eux du fait d\u2019une trop faible charge virale. Les 313 g\u00e9notypes identifi\u00e9s se r\u00e9partissaient entre le A (27,2%), le B (6,7%), le C (5,1%), le D (25,2%), le E (35,5%) et le F (0,3%).<br \/>\nL\u2019AgHBs quantitatif et la charge virale B quantitative n\u2019apparaissaient pas corr\u00e9l\u00e9s (R2 0,07, p 0,26). Aucune diff\u00e9rence de charge virale n\u2019\u00e9tait constat\u00e9e en fonction du g\u00e9notype viral.<\/p>\n<p>Conclusion : nous avons inclus pr\u00e8s de 700 porteurs inactifs de l\u2019AgHBs, l\u2019\u00e9tude des 496 dossiers suffisamment renseign\u00e9s \u00e0 ce jour montre une population relativement jeune, comparable \u00e0 la population nationale pour le sex ratio et l\u2019IMC. Nos patients sont en revanche majoritairement originaires d\u2019Afrique, infect\u00e9s principalement par les g\u00e9notypes E, A, D, avec une antig\u00e9n\u00e9mie \u00e9lev\u00e9e. L\u2019existence d\u2019une fraction significative de patients \u00e0 charge virale \u00e9lev\u00e9e (18,1%) donnera un int\u00e9r\u00eat particulier \u00e0 leur surveillance dans les 5 ans \u00e0 venir.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>2017 Marone D (1), Causse X (1), Potier P (1), Labadie H (1), Macaigne G (1), Cadranel JF (1), Salloum H (1), Henrion J (1), Renou C (1), Zanditenas D (1), Hommel S (1), Ollivier-Hourmand I (3), Arpurt JP (1), Bresson-Hadni S (2), Fontanges T (2), Schnee M (1), Boyer N (2), Bettan L (1), [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_exactmetrics_skip_tracking":false,"_exactmetrics_sitenote_active":false,"_exactmetrics_sitenote_note":"","_exactmetrics_sitenote_category":0,"footnotes":""},"categories":[3],"tags":[28],"class_list":["post-2063","post","type-post","status-publish","format-standard","hentry","category-hepatologie","tag-28"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.2 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Description de la population incluse dans l\u2019\u00e9tude de surveillance des porteurs inactifs de l\u2019antig\u00e8ne HBs (PIBAC). - Abstracts des congr\u00e8s de l&#039;ANGH<\/title>\n<meta name=\"description\" content=\"ANGH R\u00e9sum\u00e9s congr\u00e8s H\u00e9patologie Gastroent\u00e9romogie Hepatology Gastroenterology Etudes cliniques Clinical study\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/angh.net\/abstracts\/description-de-la-population-incluse-dans-letude-de-surveillance-des-porteurs-inactifs-de-lantigene-hbs-pibac-2\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Description de la population incluse dans l\u2019\u00e9tude de surveillance des porteurs inactifs de l\u2019antig\u00e8ne HBs (PIBAC). - Abstracts des congr\u00e8s de l&#039;ANGH\" \/>\n<meta property=\"og:description\" content=\"ANGH R\u00e9sum\u00e9s congr\u00e8s H\u00e9patologie Gastroent\u00e9romogie Hepatology Gastroenterology Etudes cliniques Clinical study\" \/>\n<meta property=\"og:url\" content=\"https:\/\/angh.net\/abstracts\/description-de-la-population-incluse-dans-letude-de-surveillance-des-porteurs-inactifs-de-lantigene-hbs-pibac-2\/\" \/>\n<meta property=\"og:site_name\" content=\"Abstracts des congr\u00e8s de l&#039;ANGH\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/ANGH-2136322560030484\/\" \/>\n<meta property=\"article:published_time\" content=\"2017-10-01T00:00:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2018-10-20T16:40:22+00:00\" \/>\n<meta name=\"author\" content=\"abstracts\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"abstracts\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/angh.net\/abstracts\/description-de-la-population-incluse-dans-letude-de-surveillance-des-porteurs-inactifs-de-lantigene-hbs-pibac-2\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/angh.net\/abstracts\/description-de-la-population-incluse-dans-letude-de-surveillance-des-porteurs-inactifs-de-lantigene-hbs-pibac-2\/\"},\"author\":{\"name\":\"abstracts\",\"@id\":\"https:\/\/angh.net\/abstracts\/#\/schema\/person\/f532083854369dca4b9f509cfbad90e1\"},\"headline\":\"Description de la population incluse dans l\u2019\u00e9tude de surveillance des porteurs inactifs de l\u2019antig\u00e8ne HBs (PIBAC).\",\"datePublished\":\"2017-10-01T00:00:00+00:00\",\"dateModified\":\"2018-10-20T16:40:22+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/angh.net\/abstracts\/description-de-la-population-incluse-dans-letude-de-surveillance-des-porteurs-inactifs-de-lantigene-hbs-pibac-2\/\"},\"wordCount\":619,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/angh.net\/abstracts\/#organization\"},\"keywords\":[\"2017\"],\"articleSection\":[\"Hepatologie\"],\"inLanguage\":\"fr-FR\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/angh.net\/abstracts\/description-de-la-population-incluse-dans-letude-de-surveillance-des-porteurs-inactifs-de-lantigene-hbs-pibac-2\/\",\"url\":\"https:\/\/angh.net\/abstracts\/description-de-la-population-incluse-dans-letude-de-surveillance-des-porteurs-inactifs-de-lantigene-hbs-pibac-2\/\",\"name\":\"Description de la population incluse dans l\u2019\u00e9tude de surveillance des porteurs inactifs de l\u2019antig\u00e8ne HBs (PIBAC). - Abstracts des congr\u00e8s de l&#039;ANGH\",\"isPartOf\":{\"@id\":\"https:\/\/angh.net\/abstracts\/#website\"},\"datePublished\":\"2017-10-01T00:00:00+00:00\",\"dateModified\":\"2018-10-20T16:40:22+00:00\",\"description\":\"ANGH R\u00e9sum\u00e9s congr\u00e8s H\u00e9patologie Gastroent\u00e9romogie Hepatology Gastroenterology Etudes cliniques Clinical study\",\"breadcrumb\":{\"@id\":\"https:\/\/angh.net\/abstracts\/description-de-la-population-incluse-dans-letude-de-surveillance-des-porteurs-inactifs-de-lantigene-hbs-pibac-2\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/angh.net\/abstracts\/description-de-la-population-incluse-dans-letude-de-surveillance-des-porteurs-inactifs-de-lantigene-hbs-pibac-2\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/angh.net\/abstracts\/description-de-la-population-incluse-dans-letude-de-surveillance-des-porteurs-inactifs-de-lantigene-hbs-pibac-2\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\/\/angh.net\/abstracts\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Description de la population incluse dans l\u2019\u00e9tude de surveillance des porteurs inactifs de l\u2019antig\u00e8ne HBs (PIBAC).\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/angh.net\/abstracts\/#website\",\"url\":\"https:\/\/angh.net\/abstracts\/\",\"name\":\"Abstracts des congr\u00e8s de l&#039;ANGH\",\"description\":\"Base de donn\u00e9es des abstracts du congr\u00e8s depuis 2003\",\"publisher\":{\"@id\":\"https:\/\/angh.net\/abstracts\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/angh.net\/abstracts\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/angh.net\/abstracts\/#organization\",\"name\":\"ANGH\",\"url\":\"https:\/\/angh.net\/abstracts\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/angh.net\/abstracts\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/angh.net\/abstracts\/wp-content\/uploads\/sites\/2\/2018\/10\/logo_angh_2018_-48px.jpg\",\"contentUrl\":\"https:\/\/angh.net\/abstracts\/wp-content\/uploads\/sites\/2\/2018\/10\/logo_angh_2018_-48px.jpg\",\"width\":48,\"height\":18,\"caption\":\"ANGH\"},\"image\":{\"@id\":\"https:\/\/angh.net\/abstracts\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/ANGH-2136322560030484\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/angh.net\/abstracts\/#\/schema\/person\/f532083854369dca4b9f509cfbad90e1\",\"name\":\"abstracts\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/secure.gravatar.com\/avatar\/2bb25d9cedd377e33f0ebc4fb5994a2f9d3e02f897704acdcc173c15b7c75253?s=96&d=mm&r=g\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/2bb25d9cedd377e33f0ebc4fb5994a2f9d3e02f897704acdcc173c15b7c75253?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/2bb25d9cedd377e33f0ebc4fb5994a2f9d3e02f897704acdcc173c15b7c75253?s=96&d=mm&r=g\",\"caption\":\"abstracts\"},\"url\":\"https:\/\/angh.net\/abstracts\/author\/abstracts\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Description de la population incluse dans l\u2019\u00e9tude de surveillance des porteurs inactifs de l\u2019antig\u00e8ne HBs (PIBAC). - Abstracts des congr\u00e8s de l&#039;ANGH","description":"ANGH R\u00e9sum\u00e9s congr\u00e8s H\u00e9patologie Gastroent\u00e9romogie Hepatology Gastroenterology Etudes cliniques Clinical study","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/angh.net\/abstracts\/description-de-la-population-incluse-dans-letude-de-surveillance-des-porteurs-inactifs-de-lantigene-hbs-pibac-2\/","og_locale":"fr_FR","og_type":"article","og_title":"Description de la population incluse dans l\u2019\u00e9tude de surveillance des porteurs inactifs de l\u2019antig\u00e8ne HBs (PIBAC). - Abstracts des congr\u00e8s de l&#039;ANGH","og_description":"ANGH R\u00e9sum\u00e9s congr\u00e8s H\u00e9patologie Gastroent\u00e9romogie Hepatology Gastroenterology Etudes cliniques Clinical study","og_url":"https:\/\/angh.net\/abstracts\/description-de-la-population-incluse-dans-letude-de-surveillance-des-porteurs-inactifs-de-lantigene-hbs-pibac-2\/","og_site_name":"Abstracts des congr\u00e8s de l&#039;ANGH","article_publisher":"https:\/\/www.facebook.com\/ANGH-2136322560030484\/","article_published_time":"2017-10-01T00:00:00+00:00","article_modified_time":"2018-10-20T16:40:22+00:00","author":"abstracts","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":"abstracts","Dur\u00e9e de lecture estim\u00e9e":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/angh.net\/abstracts\/description-de-la-population-incluse-dans-letude-de-surveillance-des-porteurs-inactifs-de-lantigene-hbs-pibac-2\/#article","isPartOf":{"@id":"https:\/\/angh.net\/abstracts\/description-de-la-population-incluse-dans-letude-de-surveillance-des-porteurs-inactifs-de-lantigene-hbs-pibac-2\/"},"author":{"name":"abstracts","@id":"https:\/\/angh.net\/abstracts\/#\/schema\/person\/f532083854369dca4b9f509cfbad90e1"},"headline":"Description de la population incluse dans l\u2019\u00e9tude de surveillance des porteurs inactifs de l\u2019antig\u00e8ne HBs (PIBAC).","datePublished":"2017-10-01T00:00:00+00:00","dateModified":"2018-10-20T16:40:22+00:00","mainEntityOfPage":{"@id":"https:\/\/angh.net\/abstracts\/description-de-la-population-incluse-dans-letude-de-surveillance-des-porteurs-inactifs-de-lantigene-hbs-pibac-2\/"},"wordCount":619,"commentCount":0,"publisher":{"@id":"https:\/\/angh.net\/abstracts\/#organization"},"keywords":["2017"],"articleSection":["Hepatologie"],"inLanguage":"fr-FR"},{"@type":"WebPage","@id":"https:\/\/angh.net\/abstracts\/description-de-la-population-incluse-dans-letude-de-surveillance-des-porteurs-inactifs-de-lantigene-hbs-pibac-2\/","url":"https:\/\/angh.net\/abstracts\/description-de-la-population-incluse-dans-letude-de-surveillance-des-porteurs-inactifs-de-lantigene-hbs-pibac-2\/","name":"Description de la population incluse dans l\u2019\u00e9tude de surveillance des porteurs inactifs de l\u2019antig\u00e8ne HBs (PIBAC). - Abstracts des congr\u00e8s de l&#039;ANGH","isPartOf":{"@id":"https:\/\/angh.net\/abstracts\/#website"},"datePublished":"2017-10-01T00:00:00+00:00","dateModified":"2018-10-20T16:40:22+00:00","description":"ANGH R\u00e9sum\u00e9s congr\u00e8s H\u00e9patologie Gastroent\u00e9romogie Hepatology Gastroenterology Etudes cliniques Clinical study","breadcrumb":{"@id":"https:\/\/angh.net\/abstracts\/description-de-la-population-incluse-dans-letude-de-surveillance-des-porteurs-inactifs-de-lantigene-hbs-pibac-2\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/angh.net\/abstracts\/description-de-la-population-incluse-dans-letude-de-surveillance-des-porteurs-inactifs-de-lantigene-hbs-pibac-2\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/angh.net\/abstracts\/description-de-la-population-incluse-dans-letude-de-surveillance-des-porteurs-inactifs-de-lantigene-hbs-pibac-2\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"https:\/\/angh.net\/abstracts\/"},{"@type":"ListItem","position":2,"name":"Description de la population incluse dans l\u2019\u00e9tude de surveillance des porteurs inactifs de l\u2019antig\u00e8ne HBs (PIBAC)."}]},{"@type":"WebSite","@id":"https:\/\/angh.net\/abstracts\/#website","url":"https:\/\/angh.net\/abstracts\/","name":"Abstracts des congr\u00e8s de l&#039;ANGH","description":"Base de donn\u00e9es des abstracts du congr\u00e8s depuis 2003","publisher":{"@id":"https:\/\/angh.net\/abstracts\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/angh.net\/abstracts\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/angh.net\/abstracts\/#organization","name":"ANGH","url":"https:\/\/angh.net\/abstracts\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/angh.net\/abstracts\/#\/schema\/logo\/image\/","url":"https:\/\/angh.net\/abstracts\/wp-content\/uploads\/sites\/2\/2018\/10\/logo_angh_2018_-48px.jpg","contentUrl":"https:\/\/angh.net\/abstracts\/wp-content\/uploads\/sites\/2\/2018\/10\/logo_angh_2018_-48px.jpg","width":48,"height":18,"caption":"ANGH"},"image":{"@id":"https:\/\/angh.net\/abstracts\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/ANGH-2136322560030484\/"]},{"@type":"Person","@id":"https:\/\/angh.net\/abstracts\/#\/schema\/person\/f532083854369dca4b9f509cfbad90e1","name":"abstracts","image":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/secure.gravatar.com\/avatar\/2bb25d9cedd377e33f0ebc4fb5994a2f9d3e02f897704acdcc173c15b7c75253?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/2bb25d9cedd377e33f0ebc4fb5994a2f9d3e02f897704acdcc173c15b7c75253?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/2bb25d9cedd377e33f0ebc4fb5994a2f9d3e02f897704acdcc173c15b7c75253?s=96&d=mm&r=g","caption":"abstracts"},"url":"https:\/\/angh.net\/abstracts\/author\/abstracts\/"}]}},"_links":{"self":[{"href":"https:\/\/angh.net\/abstracts\/wp-json\/wp\/v2\/posts\/2063","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/angh.net\/abstracts\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/angh.net\/abstracts\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/angh.net\/abstracts\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/angh.net\/abstracts\/wp-json\/wp\/v2\/comments?post=2063"}],"version-history":[{"count":0,"href":"https:\/\/angh.net\/abstracts\/wp-json\/wp\/v2\/posts\/2063\/revisions"}],"wp:attachment":[{"href":"https:\/\/angh.net\/abstracts\/wp-json\/wp\/v2\/media?parent=2063"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/angh.net\/abstracts\/wp-json\/wp\/v2\/categories?post=2063"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/angh.net\/abstracts\/wp-json\/wp\/v2\/tags?post=2063"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}